Equity Instruments (Tables)
|
3 Months Ended |
Mar. 31, 2022 |
Equity [Abstract] |
|
Schedule of Shares of Common Stock Reserved for Issuance |
Shares of common stock reserved for issuance on an “as if converted” basis were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
|
2022 |
|
2021 |
|
(share data) |
Common stock warrants |
13,075,000 |
|
|
13,075,000 |
|
Restricted stock units issued and outstanding |
4,549,179 |
|
|
4,041,346 |
|
Stock options issued and outstanding |
20,786,579 |
|
|
21,191,226 |
|
Shares available for future grant under 2021 Equity Incentive Plan |
26,207,150 |
|
|
17,533,471 |
|
Reserved for employee stock purchase plan |
5,495,601 |
|
|
3,663,277 |
|
Total shares of common stock reserved
|
70,113,509
|
|
|
59,504,320
|
|
|
Schedule of Warrants for Shares of Stock |
Warrants for shares of common stock consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2022 |
|
Issue Date |
|
Expiration Date |
|
Number of Warrants |
|
Exercise Price per warrant |
|
Fair Value on Issue Date per warrant |
|
Fair Value on March 31, 2022 |
|
|
|
|
|
|
|
|
|
|
|
(In thousands) |
Private placement warrants - Common Stock |
12/02/2020 |
|
09/29/2026 |
|
4,450,000 |
|
|
$11.50 |
|
$2.00 |
|
9,434 |
|
Public warrants - Common Stock |
12/02/2020 |
|
09/29/2026 |
|
8,625,000 |
|
|
$11.50 |
|
$3.30 |
|
18,285 |
|
|
|
|
|
|
13,075,000 |
|
|
|
|
|
|
$ |
27,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2021 |
|
Issue Date |
|
Expiration Date |
|
Number of Warrants |
|
Exercise Price per warrant |
|
Fair Value on Issue Date per warrant |
|
Fair Value on December 31, 2021 |
|
|
|
|
|
|
|
|
|
|
|
(In thousands) |
Private placement warrants - Common Stock |
12/02/2020 |
|
09/29/2026 |
|
4,450,000 |
|
|
$11.50 |
|
$2.00 |
|
7,387 |
|
Public warrants - Common Stock |
12/02/2020 |
|
09/29/2026 |
|
8,625,000 |
|
|
$11.50 |
|
$3.30 |
|
14,318 |
|
|
|
|
|
|
13,075,000 |
|
|
|
|
|
|
$ |
21,705 |
|
|
Warrant Liability Rollforward |
The liability for private placement and public warrants on common stock carried at fair value was as follows for the three months ended March 31, 2022:
|
|
|
|
|
|
|
|
|
March 31, |
|
2022 |
|
|
|
(In thousands) |
Beginning Balance |
$ |
21,705 |
|
|
|
Loss on fair value of warrants |
$ |
6,014 |
|
|
|
Ending Balance |
$ |
27,719 |
|
|
|
The liability for warrants on redeemable convertible preferred stock (carried at fair value) was as follows for the three months ended March 31, 2022 and 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2022 |
|
2021 |
|
(in thousands) |
Beginning Balance |
$ |
— |
|
|
$ |
181 |
|
Issuance of new warrant |
— |
|
|
— |
|
Change in fair value (Other income (expense), net) |
— |
|
|
1,514 |
|
Exercise of warrants (Redeemable preferred convertible stock) |
— |
|
|
— |
|
Ending Balance |
$ |
— |
|
|
$ |
1,695 |
|
|
Fair Value Assumptions |
The fair value assumptions used in the Monte Carlo simulation model for the recurring valuation of the private placement common stock warrants and public common stock warrant liability were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2022 |
|
As of December 31, 2021 |
Current stock price |
$ |
9.31 |
|
|
$ |
7.81 |
|
Expected volatility |
34.8 |
% |
|
40.5 |
% |
Risk-free interest rate |
2.4 |
% |
|
1.2 |
% |
Dividend rate |
— |
% |
|
— |
% |
Expected Term (years) |
4.5 |
|
4.75 |
Assumptions used in the fair value of the contingent earnout liabilities are described below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2022 |
|
As of December 31, 2021 |
Current stock price |
$9.31 |
|
$7.81 |
Expected volatility |
50.8% |
|
52.5% |
Risk-free interest rate |
2.4% |
|
1.2% |
Dividend yield |
—% |
|
—% |
Expected Term (years) |
4.50 |
|
4.75 |
|
Schedule Of Contingent Earnout Liabilities |
The rollforward for the contingent earnout liabilities was as follows for the three months ended March 31, 2022:
|
|
|
|
|
|
|
|
|
March 31, |
|
2022 |
|
|
|
(In thousands) |
Beginning Balance |
$ |
111,487 |
|
|
|
Gain on fair value of contingent earnout liabilities |
31,232 |
|
|
|
Ending Balance |
$ |
142,719 |
|
|
|
|